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A b s t r a c t  
The application of nanotechnology for the treatment, diagnosis, monitoring, and control of biological 
systems has recently been determined by the National of Health (NIH) as nanomedicine. The 
strategy of Nanoparticle delivery plays a significant impact on global Pharmaceutical planning and 
marketing. Polymeric nanoparticles are used to control the drug release, to improve the dissolution 
of poorly soluble drugs in addition to improve the bioavailability of degradable substances such as 
protein. They also enhance the uptake of hydrophilic substances across the epithelial layers and 
have the potential for intracellular drug delivery. The submicron size range of nanoparticles is not 
only suitable for parenteral application but also applicable for mucosal routes of administration, i.e., 
oral, nasal, and ocular mucosa which are non-invasive route. Thus nanoparticle formulations are 
more advantageous over traditional dosage forms. The main aim of the present review deals with 
the nanoparticles of chitosan, which is a natural and bio-degradable polymer. The review focuses on 
the isolation, purification, characteristic features, derivatives of chitosan, preparation techniques, 
evaluation methods and applications of chitosan nanoparticles. 
Keywords: chitosan, nanoparticles, bioavailability, biodegradable polymer. 
 
Introduction 
In the present scenario, nanotechnologies have gained significance 
and revolutionized the application of medicines. Before 1970 there 
was a false notion that pharmaceutical suspensions cannot be 
administered through I.V route but a research paper of „Peter 
Speiser‰ in 1976 showed that nanoparticles of antigen can be 
prepared for the purpose of vaccination and the activity can be 
sustained for a better immune response [1].  „Christian de Duve‰ 
was awarded nobel prize for the discovery of lysomotropic effect of 
the nanoparticles and also showed that nanocapsules can 
incorporate compounds into biological cells which cannot permeate 
through the cellular barriers[2][3].   
Nanoparticles (NPs) are familiar for transporting drugs, release the 
drugs in the target site which mostly undergo degradation in the 
biological fluids and for drugs that cannot readily diffuse across the 
barriers [4]. They are used to control and manipulate drugs which 
are essential for betterment of human health, and biomolecules 
which are essential for life and to improve the quality of life [5]. 
Nanoparticles that are formulated with water insoluble polymers 
use organic solvents, heat or high shear force which may affect the 
stability of the drugs. Moreover, the preparation methods are 
complex and time consuming. In contrast, water-soluble polymers 
offer mild and simple preparation methods without the use of 
organic solvent and high shear force. Among water-soluble 
polymers available, chitosan is one of the most extensively studied. 
Chitosan is a natural polymer with biocompatibility, 
biodegradability, hydrophilicity and protective properties, broadly 
used in the delivery of peptides, proteins and polynucleotides, due  
 
 
to maintaining the structure, activity and protect from degradation. 
As it is hydrogel in nature it prolongs the in-vivo circulation time of 
the components.[6] Each and every chemical entity contains its 
own inherent physicochemical properties like charge, lipophilicity, 
solubility, particle diameter, geometry, and aggregation tendencies 
which can be modified to enable different pharmacological 
activities [7, 8]. So physicochemical properties affects the 
biocompatibility and bioavailability which inturn influence the 
administration of the drugs, so such a modification of 
physicochemical properties of chemical entity for pharmacological 
activity and biocompatibility through nanoparticle approach is a 
novel and prominent  area of research in the drug delivery[9]. 
Surface modification of these nanoparticulate systems with 
hydrophilic polymers is the most common way to control the 
opsonization process and to improve the surface properties of the 
system.   
Chitosan nanoparticles have the potential to chelate metal ions 
such as palladium, copper, silver, iodine catalyst which can be 
used in health products, and insecticides. The derivatives of 
chitosan such as cyanoethyl chitosan are widely used in dialysis 
and insulating papers, hydroxy ethyl glycol chitosan in 
enzymological studies and dialysis and glutaraldehyde chitosan 
used in enzyme immobilization [10]. 
Low molecular weight chitosan nanoparticles are having good 
solubility, biocompatibility, active in biological systems, and hence  
used to deliver the non-viral vector gene [11, 12, 13]. The reactions 
between „thiol‰ and primary amino groups of chitosan produce 
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thiomers. Thiolation of chitosan forms a disulfide bond with 
glycoproteins of mucus thereby enhancing the mucoadhesive 
nature, increases permeation, and also observed the antiprotease 
activity [14]. Several thiolated derivatives of chitosan have been 
synthesized like chitosan cysteine [15], chitosan-thiobutylamidine, 
chitosan-thioglycolic acid [16] and chitosan-glutathione conjugates 
[17]. 
Recently tri-methyl chitosan nanoparticles are developed to deliver 
the vaccines and showed the maximum immune responses in 
mice, indicating that trimethyl coated chitosan nanoparticles are 
potential carriers of vaccines [18]. 
This review is an overview of chitosan and chitosan nanoparticles 
and focuses on isolation, purification, characteristic features, 
derivatives of chitosan, stability, preparation techniques of chitosan 
nanoparticles, evaluation methods and its applications. 
Chitosan 
Chitosan is a heteropolymer and it consists of β (1-4) 2-acetamido-
2-deoxy-β-D-glucopyranose (N-acetyl glucosamine) and 2-amino-
2-deoxy-β-D-glucopyranose (D-glucosamine) units, randomly or 
distributed as blocks throughout the biopolymer. It is the N-
deacetylated derivative of chitin, but the N-deacetylation is almost 
never complete (19). Chitosan has one primary amine group and 
two free hydroxyl groups for each monomer with a unit formula of 
C6H11O4N with the molecular weight of 3.8 ă 2000KD.[20]  
Chitosan exists as off white to yellow colored course ground flakes, 
and powder with glass transition temperature 203ÀC and degree of 
deacetylation is 50-95%. [21-23] 
 
 
Figure 2 Structure of (A) Chitin and (B) Protonated Chitosan 
 
Solubility of Chitosan 
Solubility of chitosan in organic acids was limited, but it is soluble in 
acids like acetic acid, formic acid, and lactic acid. The effect of pH 
was more predominant in dissolving chitosan. While preparing the 
solution the pH must be adjusted to below 6, at this pH the 
protonation of amino groups will takes place producing NH3+ ion 
which is an important prerequisite for dissolving chitosan. 1% 
acetic acid concentration is the most commonly used for dissolving, 
also it is also soluble in 1% hydrochloric acid. But it is insoluble in 
inorganic acids like „sulphuric acid, and phosphoric acids‰.  
As previously mentioned solubility of chitosan solution is mostly 
affected by pH, and itÊs solution stability also affected by pH, above 
pH 7 the stability of chitosan solution was poor. At pH below 4 it 
forms a stable solution. It forms a precipitation or gelation and poly 
ion complex which results in formation of gel at higher pH(>7).[24] 
Production of Chitosan 
Production of chitosan takes place in four steps. They are  
De-acetylation 
De-proteinization 
Demineralization  
De-colorization   
Depending on the source and method of preparation and also on 
physiological conditions, chitosan is not a single chemical entity, 
but varies in composition. Chitosan is a deacetylated form of chitin 
to form a soluble amine salts. The acetyl content must be less than 
4- 4.5% to form the soluble product and the degree of 
deacetylation must be 80 to 85% or higher. Commercially, it is 
manufactured by a chemical method. First, wash the sources such 
as crab or shrimp shells and grinded into powdered form and then 
it is deproteinized by treatment with an aqueous 3-5% solution of 
sodium hydroxide. Then it is neutralized and demineralized at a 
room temperature by treating it with aqueous 3-5% of hydrochloric 
solution to form a white or slightly pink precipitate of chitin. Then 
chitin is deacetylated by treatment with an aqueous 40-45% of 
sodium hydroxide solution and the precipitate is then washed with 
water. The insoluble part is removed using an aqueous 2% acetic 
acids solution. The supernatant solution is then neutralized with an 
aqueous sodium hydroxide solution to obtain a purified chitosan. 
[25] The extent of deacetylation mainly depends upon alkali 
concentration, time and temperature employed throughout the 
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process. For example, increasing temperature or strength of 
sodium ydroxide solution can remove acetyl groups, resulting in 
chitosan molecules of varied range of molecular weight with 
different physicochemical properties and applications. 
Degree of deacetylation 
Chitosan is a semi-crystalline polymer and the degree of 
crystallinity is a function of the degree of deacetylation. The nature 
of crystallinity is maximum for both chitin (0% deacetylated) and 
chitosan (100% deacetylated). Chitin is N-deacetylated to such an 
extent that the formed chitosan becomes soluble in dilute aqueous 
acids. The process of deacetylation involves the removal of acetyl 
groups from the molecular chain of chitin, leaving behind a free 
amino group (-NH2). Chitosan versatility depends mainly on the 
degree of chemically reactive amino groups. To increase the amino 
group content of chitosan and higher deacetylation, chitosan is 
subjected to repeated alkaline treatment. Increasing either the 
temperature or strength of the alkaline solution can also enhance 
the removal of acetyl groups from chitin.  The degree of 
deacetylation in chitosan is the ratio of 2-acetamido-2-deoxy-D-
glucopyranose to 2-amino-2-deoxy-D-glucopyranose structural 
units. The degree of deacetylation of chitosan, which determines 
the content of free amino groups, can be employed to differentiate 
between chitin and chitosan. Commercially available chitosan has 
degree of deacetylation ranging from 50 to 90%. Conversion of 
chitin into chitosan increases degree of deacetylation, and thereby 
alters the charge distribution of chitosan molecules. It is known that 
the charge density along the chain increases with an increase in 
the degree of deacetylation, and the chain flexibility of chitosan 
molecules can be manipulated by changing the degree of 
deacetylation.[26] 
Determination of deacetylation of chitosan 
Degree of deacetylation of chitosan was determined by titrimetric 
method. In this method, 1% chitosan solution prepared using acetic 
acid was added to phosphoric acid in the ratio of 1:1 (v/v) and the 
mixture was titrated against 0.1M NaOH using phenolphthalein as 
an indicator. The degree of deacetylation of the chitosan can be 
obtained using the following formula     
 
 Where m = amount of chitosan (mg) used and V = difference of 
the 0.1 M NaOH used between the chitosan solution and standard. 
Purification of Chitosan 
Various grades of chitosan were purified by the following methods:  
Cleaning the samples by the removal of insoluble 
particles  
Disperse the chitosan in distilled water and then solubilized using 
acetic acid, followed by filtration using whatmann® filter paper 
grade 541. 
Through washing by dialysis  
In addition to first method, Chitosan was precipitated from filtered 
chitosan solution and titrated with 1 N NaOH until pH value of 8.5 
was attained followed by centrifugation and resuspending of 
chitosan in distilled water. Then the chitosan suspensions were 
dialyzed against distilled water for 2 days using dialysis tubing. 
Finally, chitosan suspensions retrieved from the dialysis tubes 
were frozen at -80ÀC and lyophilized in a freeze dryer. 
Extensive purification 
In this method, 1 ml of 10% w/v aqueous solution of sodium 
dodecyl sulfate (SDS) was added to the resuspended solution of 
chiosan and stirred for 30 min. Dithiothreitol (DTT) was also added 
directly to solution of chitosan and the mixture was heated at 90-
95ÀC with continuous stirring for 5 min in the hood. After leaving the 
solution under stirring at room temperature overnight, 3.3 ml of 5% 
w/v ethylene diamine tetra acetic acid (EDTA) was added and 
stirred at room temperature for 2 additional hours. The water 
insoluble chitosan precipitate was collected by centrifugation at 
4,300 rpm for 30 min and washed several times with distilled water 
by resuspending and re-centrifugation for 30 min. Chitosan was 
resuspended in distilled water and dialyzed for 2 days using 
dialysis tubing, changing the water triplicate. Finally, chitosan 
suspensions were retrieved from the dialysis tubes, frozen at -80ÀC 
and lyophilized. 
Derivatives of Chitosan 
Chitosan has large number of applications in pharmaceutical 
dosage forms and its further application can be exploited by 
modification of basic structure to obtain derivatives with wide range 
of properties. 
N-Trimethylene chloride chitosan 
N-Trimethylene chloride is a quaternary derivative of chitosan after 
methylation. It has superior aqueous solubility, intestinal 
permeability as well as higher absorption over a wide pH range. 
The high degree of substitution was observed with decrease in 
solubility. Quaternization of N-Trimethyl chloride chitosan 
decreases the transepithelial electrical resistance and thereby 
enhances drug absorption properties.[27] 
Trimethyl chitosan (TMC) 
The TMC can be synthesized by quaternization of the amino 
groups of the parent polymer. The quaternization methods include 
use of methylating agent as methyl iodide and dimethylsulfate or 
the sequence of reductive alkylation via Schiff base formation. 
Trimethylation of chitosan generates the N, N, N-trimethyl 
derivative with permanent positive charges and water solubility. 
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TMC proved to be a derivative of chitosan with superior solubility 
and basicity, even at low degrees of quaternization, compared to 
chitosan and salts. Trimethyl chitosan nanoparticles are a superior 
vehicle for increasing the solubility of candesartan-cilexetil 
compared to trimethyl chitosan, gum arabic or commercial water 
soluble Chitosan.[28] This derivative has shown promising results 
as drug delivery agent as well as a DNA delivery agent.[29] 
Thymopentin-loaded TMC nanoparticles on oral administration 
show higher efficiency for ratio of lymphocyte CD4+/CD8 than 
thymopentin alone.[30] Self-assembled nanoparticles prepared by 
TMC and poly (gamma-glutamic acid) for oral delivery of insulin 
showed superior stability of nanoparticles in a broader pH range 
and sustained release profile of insulin with permeation 
enhancement observed.[31] Compared with non-modified TMC 
nanoparticles, alginate modified TMC nanoparticles had a stronger 
effect on enhancing drug transport through transcellular pathway 
but an equal effect on enhancing drug transport through 
paracellular pathway. TMC nanoparticles are potential carriers for 
oral protein/vaccine delivery.[32] TMC nanoparticles containing 
ovalbumin as a model antigen (TMC/OVA nanoparticles) and an 
immunopotentiator (TMC/OVA/immunopotentiator nanoparticles) 
was formulated.[33] TMC nanoparticles have been shown to 
increase the immunogenicity of subunit antigens after nasal and 
intradermal administration.  
Thiolated derivatives of chitosan  
Thiolated derivatives of chitosan known as thiomers have been 
produced via immobilization of thiol groups on the primary amino 
groups of chitosan backbone. Thiolation of chitosan has also 
demonstrated to improve the mucoadhesive properties of chitosan 
through disulfide bonds with cysteine-rich domains of mucus 
glycoproteins. Permeation enhancement and antiprotease activity 
have also been observed with thiolated chitosan. Synthesis of 
different thiolated derivatives of chitosan including chitosan 
cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid and 
chitosan-glutathione conjugates. Chitosan-glutathione conjugates 
were prepared from unmodified and thiolated polymers, 
characterized, and compared. Thiolation improves the solubility of 
Chitosan without any significant alteration in size and charge of 
nanoparticles.  Nanoparticulate system with mucoadhesion 
properties was composed of a core of polymethyl methacrylate 
surrounded by a shell of thiolated chitosan (Ch-GSH-pMMA) for 
enhancing oral bioavailability of docetaxel (DTX).The 
pharmacokinetic study was carried out in vivo using wistar rats. 
The half-life of DTX-loaded nanoparticles was about 9 times longer 
than oral DTX used as positive control. The oral bioavailability of 
DTX was increased to 68.9% for DTX-loaded nanoparticles 
compared to 6.5% for positive control. [34] Docetaxel nanoparticles 
showed a high cytotoxicity effect in the Caco-2 and MCF-7 cell 
lines after 72 hours. [35]  Nanoparticles of Letrozole prepared from  
thiolated chitosan (TCS)-dextran sulfate (DS ) may represent a 
useful approach for targeting its release at its site of absorption, 
sustaining its release and improving its mucosal availability in the 
treatment of breast cancer.[36] 
Chitosan Esters 
Chitosan esteric forms (glutamate, succinate, phthalate) have a 
different solubility profile.  These esteric forms were insoluble in 
acidic condition and provide sustained release in basic condition. 
Ordinary chitosan can be dissolved in acidic water but not in 
alkaline. Whereas Succinyl chitosan exihibits opposite behavior. It 
can function as a drug carrier for longer retention, low toxicity and 
accumulation at tumour. Chitosan (CS) esters based matrix has 
been used successfully in many formulations such as in colon-
specific oral delivery of sodium diclofenac.[37] N succinyl chitosan 
(NSC) nanoparticles had potential as a local sustained delivery 
system for hydrophobic antitumor drug, Hydroxycamptothecin. In 
vivo studies, the NSC nanoparticles showed tumor targeting and 
significant suppression of tumor growth after S.C. injection (close 
to the tumor) to mice bearing S180 sarcoma tumor. A 
histopathological analysis of the tumor tissues indicated that NSC 
nanoparticles had a lethal effect on the sarcoma cell.[38] The 5-
fluorouracil-loaded NSC nanoparticles showed good anti-tumour 
activity against Sarcoma 180 solid tumour and mild toxicity.[39] 
Chitosan conjugates 
Chitosan can be conjugated with bio-active excipients for delivery 
of active ingredients. Chitosan conjugates such as chitosan-4- 
thiobutylamidine, 5-methylpyrrolidinone chitosan, showed 
enhanced absorption as well as mucoadhesive properties. 
Chitosan is attached with the enzyme inhibitor. The polymer 
formed after attaching the enzyme retained the muco-adhesive 
properties and prevents the degradation of drugs by inhibiting 
enzymes, such as trypsin and chymotrypsin. This conjugated 
Chitosan demonstrated promise delivery of sensitive peptide drugs 
such as calcitonin.[40] The polymerădrug conjugates are 
composed of a water-soluble polymer that is chemically conjugated 
to a drug via a biodegradable spacer. The spacer is usually stable 
in the bloodstream but cleaved at the target site by hydrolysis or 
enzymatic degradation. Such drug conjugates can be selectively 
accumulated at the tumor site by the EPR effects, followed by 
release of the drug by cleavage of the spacer. Eg: Doxorubicin-
conjugated glycol chitosan (DOXăGC) with a cis-aconityl spacer, 
Low molecular weight chitosan conjugated with paclitaxel (LMWC-
PTX) was also synthesized by chemical conjugation of LMWC and 
PTX through a succinate linker, which can be cleaved at 
physiological conditions. 
Cross-linking agents used in preparation of 
nanoparticles 
Cross-linking occurs when a reagent introduces intermolecular 
bridges or cross-links between polysaccharide molecules. The 
cross-linking agent reacts with macromolecule linear chains and/or 
itself in an alkaline medium. The cross-linking drastically reduces 
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segment mobility in the polymer and a number of chains are 
interconnected by the formation of new inter chain linkages. A 
three dimensional network is then formed. If the degree of 
crosslinking is high, the matrix of the polymers becomes insoluble 
in water and organic solvents.[41]   
Classification of Cross-Linking Agents 
Cross-linking agents are broadly classified on the basis of 
interaction of cross-linkers with chitosan during cross-linking.  
Physical cross-linking 
Chemical cross-linking 
Physical cross-linking 
Polysaccharides form cross-linking network with counter ions at the 
surface. High counter ion concentration would require longer times 
to achieve complete cross-linking of the polysaccharide. This 
method gives nanoparticles with reversibility and is considered 
biocompatible due to the lack of harsh preparation condition or 
toxic crosslinkers. Ionically-crosslinked nanoparticles are generally 
pH sensitive, which is a suitable feature for stimuli-sensitive 
controlled release. Ionic cross linking occurs by using 
Tripolyphosphate (TPP), sulphuric acid, inorganic ions such as 
Fe(CN)64î, Fe(CN)63î citrate and calcium ions as cross linkers.[42]  
Chemical cross-linking 
Cross-linking agents reacts with polysaccharides forming either 
intermolecular or intramolecular covalent bonds. Covalently 
crosslinked polysaccharide nanoparticles enable the network 
structure to be permanent since irreversible chemical links are 
formed unless biodegradable or stimuli-responsive crosslinkers are 
employed. Though there is drastic change in pH, the rigid network 
allows absorption of water and bioactive compounds without 
dissolution of the nanoparticles. The concentration of cross linking 
agent and cross-linking time affects the degree of chemical cross-
linking.[41] Chemical cross-linking is carried out by using 
glutaraldehyde formaldehyde, cinnamaldehyde, genipin, low toxic 
di and tricarboxylic acids (cuccinic acid, malic acid, tartaric acid 
and citric acid) vanillin, epichlorhydrin etc., [43-50] 
Stability of Nanoparticles 
Maintaining the stability of nanoparticles is a very important aspect 
in the field of nanotechnologies with respect to pharmaceuticals, 
the nanoparticle formulations should have stability until use, or else 
the therapeutic efficacy will be lost and which shows impact on the 
human health.  
The stability of nanoparticles in suspension depends on the two 
forces like „Brownian motion and gravitational forces‰. These two 
forces play a major role in the stability. As nanoparticles are tiny 
and submicron sized particles they are in a continuous random 
motion which is called as Brownian motion, while in a random 
motion the interparticular collision may lead to settling of particles 
thereby affecting stability. The colloidal nanoparticle suspension 
may be de-stabilized by the addition of other components to the 
formulation.[51] 
The physical instability of nanoparticles is due to „agglomeration of 
particles, bridging flocculation, coagulation, hetero 
coagulation‰.[52] 
Chemical stability of nanoparticles 
It depends on the storage conditions like temperature, PH of the 
medium, composition of the formulation, type of polymer used, and 
molecular weight of polymer used in formulation. Hydrolytic 
degradable polymers will degrade at low rate if temperature and PH 
are controlled. 
E.g.  Lemoine et. al,(1996) studied the effect of type of polymer in 
stability of nanoparticles and showed that PLGA 50:50 is less 
stable than PLGA 75:25. 
For poly-caprolactone nanoparticles the initial molecular weight 
donot affect the degradation.[53]   
PH of the media also influences the stability of nanoparticles, the ph 
effect was more prominent in polylactides. The polylactide 
nanoparticles are more stable in the ph of biological fluids, at a 
temperature of 40 C. The instability of polymeric nanospheres is 
due to hydrolysis in the ph environment. In the acidic PH, it causes 
non-random cleavage of ester bonds of polymer chain by 
producing soluble derivatives including lactic-acid.   
The chemical integrity of drug in nanoparticles is another 
fundamental aspect of stability.[54] 
Most of the drugs sensitive to ph, hence ph should be optimized to 
control the leakage of drug.  During the encapsulation of strong 
hydrophilic drugs precipitation in the aqueous phase causes nano-
crystals, that may be misinterpreted as nanoparticles.[55] 
In some instances the addition of anionic-surfactants in the 
dispersion cause a more rapid degradation of polymer[PLGA], 
when strong nucleophilic groups were added in the formulation.[54] 
The storage temperature has a crucial effect on the long-term 
stability of nanoparticles.  
E.g. Polylactide and polycaprolactone nanoparticles were stored 
for 350 days at 50C, it caused only slight changes in the molecular 
weight. At 370 C there was a rapid degradation of both polymers. 
However when PLA nanoparticles were stored at 250 C, changes in 
molecular weight of polymer were observed after 4 months of 
storage.     
Stabilization of nanoparticles by lyoprotectants 
Water replacement hypothesis was considered to be the suggested 
mechanism of stabilization of nanoparticles by lyoprotectants. In 
this mechanism hydrogen bonds will be formed between the 
nanoparticles and lyoprotectants. They protect the structure of 
nanoparticles  by acting as a water substituents. Among several 
lyoprotectants disaccharides were found to be most effective 
lyoprotectants(e.g. disaccharides most effectively protect 
„griseofulvin-lipids‰ nanoparticles.[56]   
Freeze drying improves the long term stability of nanoparticles, by 
converting colloidal suspension in to solid state which will prevent 
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the aggregation of particles thereby increasing the stability of 
particles. It also prevents the breakage of polymer, which 
decreases the diffusion of drug from nanoparticles. 
E.g.  The nanocapsules of polycaprolactone were freeze dried by 
using PVP as a lyoprotectant  under extreme conditions of 
temperature and humidity and found that the nanocapsules were 
stable for 6 months.[57] 
The size of freeze-dried solid lipid nanocapsules (SLN) remained 
stable after three months of storage under two storage 
temperatures: 5 ĈC and 40 ĈC at 75% relative humidity. The stored 
nanocapsules did not exhibit any oil leakage after 3 months 
storage.[58] 
Dehydroemetine nanoparticles for treating visceral leishmaniasis 
have been freeze-dried using glucose 5% as cryoprotectant. These 
freeze-dried nanoparticles could be stored at î20 ĈC for 24 months 
without any modification of their size or the level of drug 
binding.[59] 
Freeze dried of solid lipid nanoparticles of Azidothymine with 
trehalose was found to be more stable, when compared to other 
stabilizers.[60] 
The stability studies of poly (methylidene malonate 2.1.2) (PMM 
212) nanoparticles which were freeze dried   was conducted. The 
tests were performed for a period of 12 months under various 
storage conditions of temperature and light. By conducting the test 
it was observed that PMM 212 nanoparticles showed significant 
changes at 400 c, the alterations are decrease in PH of suspension, 
modification of HPLC chromatogram of compounds, and the 
reduction of in-vitro cytotoxicity. PMM 212 is lyophilized and it 
retained itÊs properties in darkness, at room temperature, and in 
light.[61].      
Some of cryoprotectants used in literature for the freeze-drying of 
nanoparticles 
 
Glucose [62] 
Sucrose [63] 
Trehalose [64] 
Lactose [65] 
Mannitol [66] 
Sorbitol [67] 
Aerosil (colloidal silicon dioxide) [68] 
Maltose [64] 
Poly(vinyl pyrrolidone) [69] 
Fructose [70] 
Dextran [71] 
Glycerol [66] 
Poly(vinyl alcohol [71] 
Glycine, Gelatine [72] 
Hydroxypropyl-β-cyclodextrin [73] 
Mechanisms Of Drug Release From The Polymer [74]    
The delivery of drug form the polymeric carrier involves any one of 
the following steps. 
After ingestion of the formulation,  
The polymeric nanoparticles absorb water and starts swelling 
followed by diffusion of drug from the swollen matrix of the 
polymer. 
The cleavage or degradation of the polymer by the enzymatic 
reaction at the site of drug delivery, there by the drug is released 
from the inner core. 
Dissociation of the drug from the polymer and released from the 
swelled nanoparticles. 
Preparation Methods 
Chitosan nanoparticles are prepared by various methods like  
Ionotropic Gelation  
It is the simple and easy method for the preparation of 
nanoparticles. Electrostatic interactions between cationic amino 
group of chitosan and negatively charged anions of cross-linking 
agent like TPP are responsible for the formation of nanoparticles. 
Chitosan is dissolved in acetic acid to form polymer solution. 
Crosslinking agent is added to water to produce solution. In the 
presence or absence of stabilizing agents like Tween 80, 
Polyethylene glycol, crosslinking agent is added to the chitosan 
solution to form the nanoparticles instantaneously under stirring at 
room temperature. The size and surface charge of particles can be 
modified by varying the ratio of chitosan and stabilizer.[75] 
 
Figure 3 Iontotropic gelation technique 
Premix Membrane Emulsification Technique 
The dispersed phase is prepared by dissolving the chitosan in 
water. The continuous phase is prepared from the mixture of liquid 
paraffin, petroleum ether and emulsifier. Emulsion is prepared by 
dispersing the chitosan solution in continuous phase by low-seed 
stator homogenization and then transferred into the premix 
reservoir. The coarse emulsion is extruded through the porous 
glass membrane under high pressure. The formed nanodroplets 
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were further cross-linked to obtain chitosan nanoparticles. The 
chitosan nanoparticles size from 300 nm to 1.85μm could be 
obtained by premix membrane emulsification method by changing 
the pore size of the membrane. The polydispersity index could be 
as low as 0.027 under optimized conditions. It is rapid and potential 
technique to prepare nanoparticles of uniform size.[76, 77] [Figure 
4]. 
 
          Figure 4 Premix membrane emulsification technique 
Micro emulsion Method 
In this technique, chitosan nanoparticles form in the aqueous core 
of reverse micellar droplets and subsequently cross-linked through 
glutaraldehyde. It involves addition of surfactant to n-Hexane. 
Then, chitosan in acetic solution and the cross linking agent like 
glutaraldehyde were added to surfactant/hexane mixture under 
continuous stirring at room temperature. The total setup is kept 
overnight for the formation of nanoparticles in the presence of 
surfactant. A low pressure is used to remove the organic solvent. 
The process results in the cross-linked chitosan nanoparticles. The 
excess surfactant was then removed by precipitating with CaCl2 
and the precipitant was removed by centrifugation. The final 
nanosphere suspension was dialyzed before lyophilization. This 
technique offers a narrow size distribution of less than 100 nm and 
the particle size can be controlled by varying the concentration of 
cross linking agent which alters the degree of cross linking. 
Nevertheless, some disadvantages associated with this method 
are use of organic solvent, time-consuming preparation process, 
and complexity in the washing step.[78, 79] 
Emulsification Solvent Diffusion Method 
This technique is based on the partial miscibility of an organic 
solvent with water. An O/W emulsion is obtained by injection of an 
organic phase into aqueous phase containing chitosan solution and 
stabilizing agent (i.e. poloxamer) under mechanical stirring, 
followed by high pressure homogenization. The emulsion is diluted 
by addition of large amount of water to overcome organic solvent 
miscibility in water. As a result of the diffusion of organic solvent 
into water, polymer precipitation occurs, leading to the formation of 
nanoparticles. This method is applicable for hydrophobic drug and 
showed high percentage of drug entrapment. The limitations of this 
method include harsh processing conditions (e.g., the use of 
organic solvents) and the high shear forces applied during 
nanoparticles preparation [Figure 5].  
  
 
Figure 5 Emulsification solvent diffusion method 
Polyelectrolyte Complex (PEC) 
This is the simple and mild technique for the preparation of 
nanoparticles since no harsh conditions are involved. 
Polyelectrolyte complexes are formed by self-assembly of the 
cationic charged polymer and alginate. The mechanism involved in 
the formation of complex involves the charge neutralization 
between cationic polymer and alginate due to the polyelectrolyte 
component self assembly leading to a fall in hydrophobicity. 
Several cationic polymers (i.e. gelatin, polyethyleneimine) also 
possess this property. The nanoparticles were spontaneously 
formed after addition of alginate solution into chitosan which was 
priorly dissolved in acetic acid solution, under mechanical stirring at 
room temperature. The complexes size range from 50 nm to 700 
nm.[80] [Figure 6]. 
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Figure 6 Polyelectrolyte complex technique 
 
Reverse Micellar Technique 
Preparation of ultrafine polymeric nanoparticles with narrow size 
distribution can be obtained using reverse micellar medium.[81] 
Aqueous core of the reverse micellar droplets can be used as a 
nanoreactor to prepare such particles, since the size of the reverse 
micellar droplets usually lies between 1 and 10 nm and are highly 
monodispersed.[82] In this method, the surfactant is dissolved in 
an organic solvent in order to prepare reverse micelles. To this, 
aqueous solutions of Chitosan and drug are added with constant 
vortexing to avoid any turbidity. Additional amount of water may be 
added to obtain nanoparticles of larger size. To this transparent 
solution, a cross-linking agent is added and cross-linking is 
achieved after stirring overnight. The material is dispersed in water 
and then adding a suitable salt, precipitates the surfactant out and 
the mixture is subjected to centrifugation. The supernatant solution 
is decanted which contains the drug-loaded nanoparticles. The 
aqueous dispersion is immediately dialyzed using dialysis 
membrane for about 1 h and the obtained liquid is lyophilized to get 
dry powder. [Figure 7] 
 
 
        Figure 7 Reverse micellar technique 
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Emulsion-Droplet Coalescence Method 
A nanoparticle formed under this technique involves/utilizes the 
mechanism of both emulsion cross-linking and precipitation 
methods. However, in this method, instead of crosslinking the 
stable droplets, precipitation is induced by allowing coalescence of 
Chitosan droplets with sodium hydroxide droplets. First, a stable 
emulsion containing Chitosan solution along with drug is produced  
in liquid paraffin oil and then, another stable emulsion containing 
Chitosan aqueous solution made of sodium hydroxide is produced 
in the same manner. When both emulsions are mixed under high-
speed stirring, droplets of each emulsion would collide at random 
and coalesce, thereby precipitating Chitosan droplets to give small 
size particles of chitosan nanoparticles.[83] [Figure 8 
 
 
Figure 8 Emulsion- droplet coalescence technique 
 
Spray-drying 
Spray-drying method can be used as a one-step preparation of 
nanoparticle powder. Mannitol microspheres containing chisosan 
nanoparticles-loaded protein was prepared by this technique.[84] 
Chitosanăiron oxide nanoparticles with various chitosan: Iron oxide 
ratios by spray-drying.[85] Atomic absorption spectrometry results 
implied that chitosan had strong chelation with iron. Meanwhile, 
Fe3O4 was crystallized and distributed in the chitosan matrix. 
These chitosanăiron oxide nanoparticles were stable in water with 
strong super paramagnetism. 
Emulsification and cross-linking 
In this method, chitosan nanoparticles were prepared by addition of 
cross linking agents to the w/o emulsion to hardened the particles. 
The reactive amino groups of chitosan undergo a covalent cross-
linking with the aldehyde groups of glutaraldehyde, which is added 
after the emulsion formation and, consequently, after nanoparticle 
production. The final particle size was demonstrated to be highly 
dependent on stirring speed, as well as on the extent of cross-
linking. It has many disadvantages like tedious procedures and the 
application of harsh cross-linking agents.[86, 87] [Figure 9].  
 
Figure 9 Emulsification and cross-linking technique 
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Modified ionic gelation with radical polymerization 
This method is derived from ionic gelation, but introduces a 
modification, because chitosan gelation occurs concomitantly with 
the polymerisation of acrylic acid monomers. The first step occurs 
at room temperature and consists in stirring an aqueous monomer 
solution of acrylic or methacrylic acid with an aqueous solution of 
oppositely charged chitosan. In some cases, polyethylene glycol 
(PEG) or polyether (polethylene glycol-polypropylene glycol-
polyethylene glycol) are also added to the reaction medium, either 
separately into the monomer solution or following mixing with 
chitosan.  
The opposite charges of chitosan and acrylic or methacrylic acid 
lead to an ionic interaction, while radical polymerisation of the latter 
is initiated by the addition of potassium persulfate. This reaction 
takes place under a nitrogen stream and the temperature is usually 
raised to 60 - 70 ÀC. The polymerisation reaction lasts for 
approximately 6 h, after which the formed suspension of 
nanoparticles is allowed to settle overnight. Finally, unreacted 
monomers are removed by dialysis or subsequent washes of the 
formed particles with distilled water. Parameters such as 
chitosan/acrylic monomers ratio and polymers concentration have 
been found to strongly affect the physicochemical characteristics of 
the nanoparticles properties.[88] [Figure 10]. 
 
 
Figure 10 Modified ionic gelation with radical polymerization 
Desolvation  
The method of desolvation is also frequently referred to as simple 
coacervation or phase separation and involves a macromolecular 
aggregation brought about by partial desolvation of fully solvated 
molecules. The use of desolvating agents to produce chitosan 
particles was reported for the first time for the preparation of 
micron-sized carriers. Substances such as sodium sulfate acetone 
used as precipitating agents. The preparation of chitosan 
nanoparticles by this method is very simple and mild as it involves 
the dropwise addition of the solvent competing agent of greater 
hydrophilicity (e.g. sodium sulfate) into a previously formed 
chitosan solution. As the salt enters in contact with the aqueous 
environment of chitosan solution, a progressive elimination of 
salvation water surrounding chitosan occurs as a consequence of 
the higher affinity of water for the salt. Factors such as chitosan 
molecular weight, chitosan concentration, amount of desolvating 
agent and stirring rate have been found to strongly affect the final 
characteristics of nanoparticles.[89] [Figure 11] 
 
Figure 11 Desolvation Technique. 
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Table 1:Characterization Of Chitosan Nanoparticles [90-92] 
Parameter Instrument Method/Specifications 
Compatibility  
studies 
Fourier Transform  
Infrared (FTIR) Spectra  
Studies 
Specified quantity of potassium bromide and  
samples was blended, compressed to the pellet and  
analyzed from 400 to 4000 cm-1 
Thermal analysis Differential  
scanning calorimetry  
(DSC) 
Temperature of glass transition may be determined.  
Freeze-dried nanoparticles along with  
lyoprotectant (to prevent shrinkage) were analyzed. 
Determination  
of particle size 
Scanning Electron Microscopy (SEM)
(Ex: JEOL JSM T330A)  
Dried film of nanoparticles coated on 25nm thick  
Gold coated slab 
Transmission electron microscopy 
(TEM) (Ex: JEM-100 CX, Japan) 
A drop of nanoparticle solution was placed on a copper grid with 
polyvinyl formal film 
Atomic force  
microscopy  
(Ex: Multimoda III, 
Veeco, USA) 
Samples were prepared by adsorbing the  
polysaccharide nanoparticles on a silicon substrate  
modified with a PEI and PEI/PSS sublayer and mean hydrodynamic 
diameter of swollen  
polysaccharide nanoparticles was estimated by light scattering 
Quasi-elastic light  
scattering (QELS) 
Air-cooled argon ion laser operated at 488 nm as  
Light source using 128-channel digital correlator.  
The time dependence of the intensity autocorrelation function of the 
scattered intensity was derived which gave the self-diffusion of the 
particles. 
Zeta potential  Zeta sizer  
(Ex: BrookhavenÊs Zeta Plus apparatu
(Brookhaven Instruments Corporation)
Based on electrophoretic mobility of drug  
loaded nanoparticles 
Surface analysis X-ray diffraction (XRD) Diffraction patterns of samples were obtained at room temperature 
with powder diffractometer using a Cu- Kđ radiation, a current of 30 
mA and voltage of 45KV 
X-ray diffraction  
Spectroscopy (XPS)and  
Time of flight-Secondary Ion Mass 
Spectroscopy (TOF - SIMS)[68] 
To determine their chemical composition by  
placing the sample on polished monocrystalline silicon wafer 
(Sample holder) 
XPSÆAl-Kđ radiation was passed,  
photoelectrons are collected at an angle of 900  
relative to sample surface (as monolithic spots of  
400 μm diameter, 0.1256 mm2 area ) and analyzed by constant 
analyzer energy (CAE). 
TOF-SIMSÆ Samples were bombarded with a  
pulsed bismuth ion beam (Bi3+) generated with a  
liquid metal ion gun (25 keV) and at 45À incidence.  
Secondary ions are generated are extracted with  
10kV and TOF was measured in reflectron mass  
spectrometer. 
Investigation of  
pH Sensitivity of 
Chitosan  
Nanoparticles 
pH meter, Zeta Sizer Nanoparticles were incubated for 1 and 3 h in  
phosphate buffer solutions with different pH values  
of 3, 4, 5, 6, and 7.4 (maintained by HCl (37%) and  
NaOH (50 (w/v)%) and particle size distribution was measured 
 
Evaluation Of Chitosan Nanoparticles 
Percentage yield of Nanoparticles 
Thoroughly dried nanoparticles were collected and weighed 
accurately. The percentage yield was then calculated using 
formulae given below:[93] 
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்௢௧௔௟ ௪௘௜௚௛௧ ௢௙ ௗ௥௨௚ ௔௡ௗ ௣௢௟௬௠௘௥
X 100 
 
Estimation of Amount of Drug Incorporated to Chitosan 
Nanoparticles 
Accurately weighed known quantity of drug loaded nanoparticles 
from each batch is taken and dispersed in 100 ml of normal saline 
and sonicated for half an hour. The solution is centrifuged at 10000 
rpm for 15 min, and the absorbance is determined using UV 
spectrophotometer with plain chitosan nanoparticles as reagent 
blank. [94]   
Study on In-vitro Drug Release 
The known quantity of nanoparticles is taken in a 250 ml conical 
flask and to it 100 ml of suitable buffer is added. Then the flask is 
kept in a shaker cum incubator and shaker is adjusted to 40-50 
horizontal stokes / min at 37ÀC. From this, 2 ml is withdrawn at 
various time intervals while replacing it with fresh normal saline of 2 
ml. The samples are centrifuged and filtered. From the filtrate 1 ml 
of the sample is withdrawn and diluted to 10 ml with normal saline 
and the drug content is analyzed by UV Spectrophotometer. 
Determination of Kinetics of Drug Release 
In-vitro release data obtained is fit into a suitable model in order to 
predict and correlate the release behaviour of the drug from the 
polymer matrix. Hence the dissolution data is fitted according to the 
well-known exponential equation, which is often used to describe 
the drug release behaviour from polymeric system. The equation, 
which is used to describe drug release mechanism is: 
ܯ௧
ܯஶ
ൌ ݇ݐ௡ 
Where mt/m¥ is the fraction release of the drug at timeÂtÊ, ÂkÊ is the 
constant which indicates the properties of the macromolecular 
polymer system, and ÂnÊ is the release exponent which indicates of 
the mechanism of release. The ÂnÊ value is used for the analysis of 
drug release mechanism from the drug-loaded nanoparticles.[95] 
In-vivo biodistribution Studies 
In-vivo bio distribution studies are carried out using suitable animal 
models and divided into groups. On the first day, group I is treated 
with free drug with appropriate dose intravenous route. The similar 
concentrations of drug loaded nanoparticles are administered to 
group II and suitable buffer as solvent control for group III. After 18 
h of injection, animals are sacrificed, then blood was taken and 
plasma is separated out, and also different organs like liver, lung, 
kidney and spleen are extracted out and homogenized in suitable 
buffer saline followed by centrifugation. Supernatant of the 
homogenized tissue are analyzed by using HPLC to estimate the 
bio distribution of the drug administered.[91] 
Stability study of nanoparticles 
The formulation of nanoparticles were separated into three portions 
one portion was kept at room temperature, second at 45ÀC, and 
third at 4ÀC for one month. At weakly intervals samples were 
determined spectro-photometrically using phosphate buffer saline 
pH 7.4 and drug content were estimated. 
Blood compatibility 
Whole blood was collected from healthy men of age 22ă31 years 
old, added with EDTA, and mixed thoroughly. On centrifuging 
whole blood at 1000 rpm for 20 min, red blood cells (RBCs) were 
collected. The RBCs were washed thrice with a saline solution 
before being diluted with a buffer to prepare erythrocyte stock 
solutions with fixed concentrations of hemoglobin (3:1 centrifuged 
erythrocytes: buffer saline solution). Prior to sonication,  freeze 
dried nanoparticles were redispersed  in a saline solution to give 
0.2 % suspensions. 100 μL of suspension with different 
concentrations were added to 1 ml of an erythrocyte stock solution. 
The mixtures were incubated for 1 h at 37ÀC in water bath. After 
the centrifugation at 4000 rpm for 10 min, an aliquot of the 
supernatant was analyzed spectrophotometrically, by dissolving in 
2 ml of saline. The saline solution alone was used as a negative 
control (0 % lysis) and the distilled water as a positive control (100 
% lysis). The hemoglobin   released was determined 
spectrophotometrically (UV 1650 PC Shimadzu) at 540 nm. 
Percent hemolysis was calculated using the formula 
 
% ܪ݁݉݋݈ݕݏ݅ݏ
ൌ  
ܣܾݏ݋ݎܾܽ݊ܿ݁ ݋݂ ݏܽ݉݌݈݁
ܣܾݏ݋ݎܾܽ݊ܿ݁ ݋݂ ݐ݄݁ ݌݋ݏ݅ݐ݅ݒ݁ ܿ݋݊ݐݎ݋݈
 ܺ 100 
Applications 
Parenteral administration 
Particles greater than 100 nm in diameter are rapidly taken up by 
the reticulo endothelial system (RES) in the liver, spleen, lung and 
bone marrow, while smaller-sized particles tend to have a 
prolonged circulation time. Nanosized particles can be 
administered intravenously because of small diameter blood 
capillary of approximately 4 μm. The biodistribution of 
nanoparticles can vary depending on the surface charge, size, and 
hydrophobicity of the administered particles.[96] Negatively-
charged particles are eliminated faster than positively-charged or 
neutral particles.[97] The creation of a hydrophilic coating such as 
polyethylene glycol (PEG) or a nonionic surfactant on hydrophobic 
carriers significantly prevent their uptake by opsonins and also 
improves their circulation time. Hydrophilic coating along with 
neutral surface charge is a viable approach to decrease 
macrophage phagocytosis and thereby improve the therapeutic 
efficacy of formulation. The most promising drugs that have been 
extensively used for delivery through this route are anticancer 
agents such as 5-Flurouracil, cytarabine, doxorubicin, paclitaxel 
etc. Following intravenous administration, many nanoparticles 
including chitosan nanoparticles (NP) accumulated in a number of 
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tumors. The main possible reason for the phenomenon may 
involve the leakiness of tumor vasculature.[75]  Nanoparticles for 
targeting an anti-AlzheimerÊs drug tacrine to the brain. A higher 
concentration of drug tacrine was observed in liver, spleen and 
lungs with the nanoparticles after 1 h of post injection the rats 
(decapitation method).[98] 
Peroral administration 
This route is suitable for the administration of molecules which are 
acid labile and sensitive to enzyme degradation such as 
macromolecules, proteins, polynucleotideÊs. This approach was 
extensively studied after a report that blood glucose levels were 
reduced in diabetic rats following the oral administration of insulin 
nanoparticles.[99] Limiting nanosized particles to less than 500 nm 
in diameter seems to be a key factor in permitting their transport 
through the intestinal mucosa most probably through an 
endocytosis mechanism.[100] However, besides the enzymes, 
mucus layer, which hamper diffusion of drug molecules and 
nanoparticles, and the epithelial absorption barriers are main 
hurdles against gastrointestinal protein drug absorption.[101] 
Therefore, drug bioavailability can be improved by controlling the 
particle size along with prolonging the residence time of drug 
carrier systems in GIT.[102] Among polymeric nanoparticles, 
chitosan NP showed to be attractive carriers for oral delivery 
vehicle as they promote absorption of drug. 
Non-viral gene delivery vectors 
In order to overcome the disadvantages associated with viral 
vectors like pathogenicity, host immune responses, induction of 
neoplastic growth following insertional mutagenesis, non-viral gene 
transfer systems were explored.[103] There are usually considered 
to be primary barriers for successful gene delivery because of cell 
entry, endosome escape, intracellular trafficking, and nuclear entry 
in vivo stability. Cationic polymers like chitosan and lipids both 
have shown promise as gene delivery agents since they produce 
particles of  polyatomic nature that reduce one or more of these 
barriers for absorption. For example, by collapsing DNA into 
particles of reduced negative or increased positive charge, binding 
to the cell surface and enhanced endocytosis may be promoted 
through barriers.[104] In many cases, cationic polymers offer more 
stable complexes and favoring more protection during cellular 
trafficking than cationic lipids.[105] Nanoparticles for gene delivery 
efficacy of DNA polyplexes composed of chitosan and Factor VIII 
DNA. Transgene DNA was detected in both local and systemic 
tissues following oral administration of the chitosan nanoparticles 
to hemophilia A mice. [106] 
Delivery of vaccines 
Nanoparticles may be readily taken up by antigen presenting cells 
and exhibit significant adjuvant effects in parenteral vaccine 
delivery.[107] Chitosan nanoparticles were widely apt for the 
modern vaccinology facilitated by the oral and nasal delivery of 
nanoparticles with mucosal protective immune responses. The 
submicron size of nanoparticles promotes their uptake up by M-
cells, in mucosa associated lymphoid tissue (MALT) i.e. gut-
associated, nasal-associated and bronchus-associated lymphoid 
tissue and other targeting sites of vigorous immunological 
responses.[108]. Chitosan-based DNA flu vaccine for intranasal 
administration was formulated.[109] 
Ocular administration 
The administration of nanoparticles through this route provides 
prolonged residence time by adhering to ocular epithelial tissue 
compared to conventional ophthalmologic formulations, thereby 
improving drug bioavailability. This suggests that the nanoparticles 
are potential carriers for ocular delivery.[110] As a consequence, 
nanoparticles have been developed for targeted ophthalmic 
delivery of antiallergic, anti-inflammatory and beta-blocker 
drugs.[86] Mucoadhesive chitosan sodium alginate nanoparticles 
as submicroscopic reservoirs for prolong ophthalmic delivery of 
gatifloxacin.[111] 
Dental administration 
Chitosan was widely used as an effective medicament in various 
fields of medicine and dentistry. Chitosan could be used as an anti-
inflammatory root canal dressing material for periapical lesions in 
endodontics. Chitosan stimulates the fibroblastic cells to release 
chemotactic inflammatory cytokines, especially interleukin 8 (IL-8). 
[112] Histological findings indicate that chitosan induces the 
migration of polymorphonuclear leukocytes and macrophages in 
the applied tissue at the early stage of dental disease.[113] The 
chitosan nanoparticles administered orally had the ability to hinder 
the acid tolerance response (ATR) of adhered Streptococcus 
mutans.[114]  Fluoride chitosan nanoparticles can be used for 
remineralization and prevention of dental caries.[115] 
Colon drug delivery 
Chitosan shows degradation in the colon and hence it was used in 
colon drug delivery. Hyaluronic acid-coupled chitosan 
nanoparticles bearing 5-fluorouracil (5-FU) were prepared by an 
ionotropic gelation method for the effective delivery of the drug to 
the colon tumors.[116] These nanoparticles showed enhanced 
cellular uptake by HT-29 colon cancer cells compared to the 
uncoupled nanoparticles.[117] Nanoparticles formulated with pH-
sensitive properties and specific biodegradability for colon-targeted 
delivery of satranidazole.[118] 
Liver delivery 
Chitosan nanoparticles were used for liver delivery by employing 
passive trapping of nanoparticles by reticuloendothelium or active 
targeting based on recognition between hepatic receptor and 
ligand bearing particulates.[119] Lactosaminated N-succinyl-
chitosan (Lac-Suc), synthesized by reductive amination of N-
succinyl-chitosan and lactose using sodium cyanoborohydride, as 
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a liver specific drug carrier.[120, 121] In the other study, 
glycyrrhizin (GL) was conjugated to the surface of chitosan 
nanoparticles by ionic gelation process. These nanoparticles were 
developed for a drug delivery system targeting the liver through a 
specific interaction between GL and hepatocytes. 
Kidney delivery 
Chitosan drug conjugates have been used for drug targeting to the 
kidney in the form of drug-carrier conjugates. However, drug 
conjugates often suffer from renal toxicity, cardiovascular side 
effects, and poor biocompatibility.[122, 123] Therefore, researchers 
have devoted their efforts in developing highly safe carrier systems 
for the drugs. Randomly 50% N-acetylated low molecular weight 
chitosan (LMWC) selectively accumulated in the kidneys, 
especially in the renal tubes after intravenous injection into 
mice.[98] In an attempt to develop drug delivery system for renal 
targeting, the authors conjugated prednisolone to LMWC (19 kDa) 
through a succinic acid spacer. The distribution of the conjugates in 
the kidney was found to be 13 fold higher than that of prednisolone 
alone. 
Lung delivery 
Chitosan-modified poly (lactic-coglycolic acid) nanoparticles 
containing paclitaxel (C-NPs paclitaxel) was prepared by a solvent 
evaporation method. The study demonstrated that the in vitro 
uptake of the nanoparticles by a lung cancer cell line (A549) was 
significantly increased by chitosan modification. Under acidic tumor 
conditions, C-NPs became more positive and interacted strongly 
with the negatively charged tumor cells. The enhanced interaction 
between C-NPs and tumor cells at the acidic microenvironment 
might be the underlying mechanism of lung tumor-specific 
accumulation of paclitaxel from C-NPs-paclitaxel. Formulation of 
chitosan and glycol chitosan nanoparticles containing the 
surfactant Lipoid S100 for the systemic delivery of low molecular 
weight heparin for pulmonary administration.[124] 
Cancer-targeted drug delivery 
The conventional cancer chemotherapeutics includes high toxicity 
of most anticancer drugs, following systemic administration due to 
indiscriminate distribution of drugs towards disease and healthy 
cells. In addition, anticancer drugs often suffer from poor solubility 
in water and thus need to use organic solvents or detergents for 
clinical applications, resulting in undesirable side effects such as 
venous irritation and respiratory distress. Therefore, designing a 
distinct carrier system that encapsulates a large quantity of drugs 
and specifically targets tumor cells is indispensable for successful 
cancer therapy.[125] Physical targeting using Chitosan-based 
stimuli-sensitive formulations and chitosan based magnetic 
nanoparticles are also developed. Formulation of  Doxorubicină 
dextran conjugate into long circulating CS nanoparticles to 
minimize cardiotomacromolecular drugs in tumor tissues. The 
specific passive accumulation of macromolecules occurs near the 
defective tumor vasculature with disorganized endothelium at the 
tumor site and a poor lymphatic drainage system. Since then, 
researchers have capitalized this concept for the delivery of various 
drugs by conjugating them with polymers or encapsulating within 
nanoparticles. Nowadays, it is evident that long circulating 
macromolecules (polymerădrug conjugates) and nanosized 
particulates (such as micelles and liposomes) accumulate 
passively at the tumors due to the EPR effect.[127] 
Active targeting · Receptor-mediated endocytosis 
(RME) 
The accumulation of drugs in tumor tissue does not always lead to 
the successful therapy if the drug does not reach the target site of 
the tumor cell such as the cell membrane, cytosol, or nucleus. 
Therefore, a more effective method should be discovered such that 
the therapeutic agents are able to reach their molecular targets. 
Cancer cells often over-express some specific antigens or 
receptors on their surfaces, which can be utilized as targets in 
modern nanomedicine. Active targeting can be achieved by 
chemical modification of nanosized drug carriers with targeting 
components that precisely recognize and specifically interact with 
receptors on the targeted tissue. Direct conjugation of the targeting 
moiety to drugs failed to demonstrate their improved activity on 
cancer treatment. This was due to decrease in the biological 
activity of the drugs, compromised by conjugation of the targeting 
moiety. In addition, conjugation badly affected the targeting 
molecule by disrupting receptor/ligand recognition. To avoid this 
disadvantage, researchers developed an efficient drug delivery 
system comprised of (a) active chemotherapeutic drug, (b) 
targeting moiety, and (c) a nanosized carrier made up of polymers 
or lipids. In this system, the therapeutic agents are physically 
entrapped in the carrier.[128] 
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Table 2: List of some reported Chitosan nanoparticles 
S.N     NAME OF DRUG                METHOD REFERENCES 
1 Atorvastatin calcium Solvent evaporation method [129] 
2 
Amphoteracin B 
        Ionic gelation method 
[130] 
Amoxycillin [131] 
5-Fluorouracil [132] 
Isoniazid [92] 
Dexamethasone Sodium Phosphate [133] 
Arbutin [134] 
Ampicillin trihydrate [135] 
Acyclovir [136] 
Gatifloxacin [111] 
Cytarabine [97] 
Mercaptopurine [137] 
Docetaxel [138] 
Carboplatin [139] 
Tamoxifen [140] 
Tenofovir [141] 
Thymoquinone [142] 
3 Carboplatin-Fe@C Reverse micro emulsion method [143] 
4 
Paclitaxel 
Emulsification solvent  
Evaporation 
[144] 
Bovine serum albumin [145] 
Letrozole [36] 
5 
5-fluorouracil 
Emulsion Droplet Coalescence  
Method 
[146] 
Stavudine [147] 
5-fluorouracil [148] 
6 
Salmon calcitonin 
Spray drying 
[149] 
Cetirizine dihydrochloride [150] 
Lomustine [151] 
Tramadol hcl [152] 
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Table 3: List of various patents of chitosan nanoparticles 
S.no Inventor name Publication number  
and date 
Brief result Applications Reference 
1 Marta Domingo et al. 
EP1243688 A1 
Sep 25, 2002 
Preparation of Nanochitosan of various forms  
like fibers, yarns, knitted fabrics and fabrics. 
Possess the soothing and anti-inflammatory action [153] 
2 Allan Emerson David 
 et al. 
WO2005117844 A2 Dec 15, 2005
Method development for encapsulation 
of Chitosan polymer in a surface modified network of colloid formi
materials like silica to  
form mucoadhesive nano composites. 
For the treatment of stomach ulcers 
and also serves as antibacterial. 
[154]
3 Julio Fernandes   et al. 
US20060105049 A1  
May 18, 2006 
Preparation of folic acid and chitosan Chitosan nanoparticles to deliver
therapeutic agent of  
Interest 
For the treatment of non-viral novel drug delivery 
with improved transfection efficiency 
[155] 
4 Fernandez M. 
et al. 
CA2602031 A1 
Sep 21, 2006 
Preparation of chemically modified Chitosan nanoparticles with 
polyethyleneglycol and loaded  
with bioactive agents.  
For the treatment of diseases and also serves for 
cosmetic purposes. 
[156] 
5 
Makiko Aimi  
et al.    WO2007086613 A1 Aug 2, 2007
Development of safe nanoparticles made from  
highly biocompatible materials without the use of a surfactant or 
synthetic polymer and followed by  
cross linking. 
 
Imparts safety 
[157] 
6 Sun Heang Heo   
et al. 
WO2008060096 A1  
May 22, 2008 
Preparation of folic acid conjugated water  
soluble Chitosan nanoparticles  
Served as Gene carriers and shows  
high gene expression. 
[158] 
7 Peter Kauper  
and Carsten Laue 
US20080254078 A1 Oct 16, 2008
Development of  new binary system of hydrophilic nanoparticles and 
microparticles, using chitosan and polyanionic polysaccharides 
Used as carrier systems for drugs,  
pro drugs, proteins and peptides, enzymes, vitamin
and fragrances. 
[159] 
8 
 
Alekha K. Dash, 
 William J. Trickler 
WO2008105852 A3 Nov 6, 2008 Development of Chitosan nanoparticles composed  
of glyceryl monooleate loaded with bioactive agents. 
For the treatment of  breast,  
pancreatic, colon, prostate, and other cancers 
[160] 
 
9 
Hsing-Wen Sung  
and Hosheng Tu. 
 
WO2006073950 B1 
Dec 11, 2008 
 
Introduced the method of preparation of insulin 
 loaded chitosan- poly--glutamic acid  
nanoparticles. 
To enhance the permeability for paracellular drug 
delivery of bioactive agents. 
[161] 
10 
Morten andreasen  
et al. 
WO2009010071 A  
Jan 22, 2009 
Prepatation of bio-active Osteopontin/siRNA-chitosan nanoparticles To inhibit bacterial growth and for treatment of 
bacterial infections. 
[162] 
11 
Jackie Y. Ying   
et al. 
WO2008136773 A8  
Jan 29, 2009 
Development of derivatives of chitosan oligomeric  
or polymeric glucosamines with surfactants loaded with bio-active 
agents
For the treatment of molecular  
imaging agents, biosensing agents or drug delivery
agents
[163] 
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12 Fernandez M.  
et al. 
EP2026772 A1 
Feb 25, 2009 
Development of micro- and nanoparticulated 
systems composed of chitosan (or other cationic polymers) and 
hyaluronic acid   
To improve the interaction and 
absorption of nanoparticles with epithelial barriers 
and also used for Cosmetic purposes and gene 
therapy. 
[164]
13 Emir Baki  Denkbas   et al. 
WO2009048958 A2 
Apr 16, 2009 
Formulation of siRNA incorporated chitosan  
particles and Methods introduced for delivering a therapeutic agent or 
diagnostic agent 
Helps in predicting prognosis of ovarian cancer 
ovarian cancer 
[165] 
14 Peter Kauper, and  CarstLaue 
US20090117195 A1  
May 7, 2009 
Preparation of the nanoparticles constituted by two hydrophilic polyme
like alginate and chitosan derivative 
Improves the physicochemical properties of the 
micro- or nanoparticles. 
[166] 
15 
Flemming Besenbacher 
et al. 
WO2009012786 A3 
Jun 18, 2009 
Development of chitosan-siRNA nanoparticles targeting a mRNA 
encoding a pro-inflammatory cytokines. 
For the treatment  
of inflammatory diseases 
[167] 
16 Emir Baki  Denkbas  et al. WO2009048958 A3  
Jul 16, 2009 
Development of Chitosan nanoparticles loaded with Zeste homologue 
(EZH2) for ovarian cancer.
For Predicting  the prognosis of diseases like ovari
cancer
[168] 
17 Youngnam Cho  et al. WO2009091992 A1  Jul 23, 2009 
Development of non toxic chitosan or silica  
polymer surfaced microcolloid  nanoparticles 
To target the damaged nerve tissues [169] 
18 Yue Chen et al. US20090252803 A1 Oct 8, 2009
Development of lung targeted drug delivery system where carrier is 
modified with glycyrrhetinic acid 
for loading bio-active agents
For the treatment of abdominal pain over the liver 
area, jaundice and itch. 
[170]
19 
Arun Kumar  
 et al. 
 
WO2009105278 A3 Oct 15, 2009
Pre-loading of Sertoli cells with chitosan  
nanoparticles coupled with or without the drug curcumin and pre-labele
with a fluorescent cell marker 
For the treatment of lung diseases. [171] 
20 Silke Krol and Gallardo Julian
Lopez-Viota 
EP2123262 A1 
Nov 25, 2009 
Development of gold-creatine Chitosan   
Nanoparticles
For the treatment of stroke and  
serves as neuro protective
[172] 
21 Julio C. Fernandes and  Françoise Winnik. US20090324726 A1 Dec 31, 2009
Development of nanoparticles comprising of  
Folate-PEG-chitosan conjugate and plasmid  
For the treatment of arthritis using  
gene therapy 
[173] 
22 Cheng-Hsien Chen  et al. US20100086613 A1 Apr 8, 2010
Preparation of Chitosan-DNA or Chitosan-protein complexes Used for the diagnostic, therapeutic
 and biological industrial purposes. 
[174]
23 Peter Kaeuper,  
Carstnen Laue 
US20100092572 A1 
Apr 15, 2010 
Preparation of chitosan  nanoparticles comprising  of ribonucleic acid For the treatment of genetic diseases. [175] 
24 Santosh Kumar  
et al. 
WO2010013224 A4 May 14, 2010
Introduced the methods of producing Chitosan nanoparticles loaded w
pure Curcumin  
to increase the bioavailability of the same. 
For the treatment of cancers, inflammatory disease
alzeihmer's disease, cholesterol gall stone, and 
diabetes 
[176] 
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25 
Magdolna Bodnar 
and 
Janos Borbely 
       US7740883 B2 
Jun 22, 2010 
Methods introduced for  preparing Chemically  modified chitosan 
derivatives  with one or more mono-, di-, tri- and polycarboxylic acids to
get  
nano-sized derivatives 
Chitosan derivatives used as 
detergents,  additives for pharmaceutical 
composition and for drug delivery, and DNA carrier
system 
177]
26 Moon-Hee Sung  et al. WO2010151076 A3 May 5, 2011
Development of modified chitosan nanoparticles  
using poly gamma glutamate helped in making of vaccine and Adjuvan
composition 
Increases antibody production, and made resistant
virus and bacterial infections 
[178] 
27 Swadeshmukul Santra  US20110158901 A1, Jun 30, 201
Development of Chitosan based nanoparticles incorporating diagnostic
agents and target-specific ligand. 
Used for biological imaging. [179] 
28 Sukhdeep Dhadwar et al.  WO2012040832 A1 Apr 5, 2012 
Development of Chitosan nanoparticles comprising  
a nucleic acid that encodes a therapeutic protein 
For the treatment of genetic diseases. [180] 
29 Kiran Sonaje  et al. 
US8153153 B1 
Apr 10, 2012 
Development of Chitosan- poly-glutamic acid nanoparticles with at leas
one bioactive agent 
To enhance absorption and permeability. [181] 
30 Moon-Hee Sung 
US20120164174 A1 
Jun 28, 2012 
Development of poly-gamma-glutamic acid  
chitosan nanoparticles comprising of vaccine composition 
Used in the treatment of viral and bacterial 
infections and in cancers to increase the production
of antibodies. 
[182] 
31 Ke-Ming Liang  et al. 
US8211475 B2 
Jul 3, 2012 
Preparation of  chitosan nanoparticles in water 
 Phase 
To lower the dosage of drugs thereby reduces the 
side effects caused by  
high dosage can be reduced 
[183] 
32 Noah Ben-    Shalom  et al. US20120189704 A1 
 Jul 26, 2012 
Preparation of Chitosan gels in different  
concentration s of acids at physiological pH and temperature. 
It Provides the slow-release of drugs and 
regenerative medicine. 
[184] 
33 
Hsing-Wen Sung 
et al. 
US8287905 B1 
Oct 16, 2012 
Introduced the method of preparation of insulin  loaded nanoparticles o
chitosan and γ-PGA. 
For the treatment of hypoglycemia. [185] 
34 Swadeshmukul Santra et al. US20120269729 A1 Oct 25, 2012
Development of chitosan-based nanoparticles stabilized with a 
hydrophilic dispersing agent, such as polyglutamic acid (PGA). 
Used for imaging and therapeutic drug/gene delive [186] 
35 
Rebecca A. Bader and Nan 
Zhang. US20120294904 A1 Nov 22, 2012
Development of poly(sialic acid) (PSA)-based  
N,N,N-trimethylchitosan (TMC)  nanoparticles  
loaded with Methotrexate  
For treating of  systemic diseases and neurological
disorders 
[187] 
36 Nora Dr. Laryea et al. 
EP1992230 B1 
Jul 3, 2013 
Silylation of  the natural substance like Chitosan 
 with the organosilanes to form nanoparticles  
Used for coating purpose, aircraft or watercraft, 
carpets, textile under shields and boot liners. 
[188] 
37 Cliff Wong  et al. 
US20130224282 A1 
Aug 29, 2013 
 
Development of Multistage nanoparticles using various polymers varyi
their size based on the physiological barriers. 
For the treatment and/or diagnosis of disease, e.g.
cell proliferative  
diseases such as cancer.
[189]
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Conclusion 
The review has concluded that the chitosan is the versatile 
biopolymer and has great utility in controlled release and targeting 
of the drug molecules. Chitosan nanoparticles serve as the 
promising drug delivery system because it is a natural polymer, 
with biocompatible, biodegradable and bioadhesive properties. 
Existence of Chitosan in various molecular weights and its 
chemical derivatives promotes the flexibility in the formulation 
development. Chitosan nanoparticles prepared by simple methods 
as chitosan are soluble in water. Nanosize range improves 
absorption thereby bioavailability. These may avoid degradation of 
drugs and related side effects. Chitosan nanoparticles offer 
versatile routes of administration, especially non-invasive routes 
i.e. per oral, nasal, and ocular mucosa, which are preferable routes 
of administration. These nanoparticles serves as a promising drug 
delivery and  are suitable for the wide range of drugs like 
macromolecules, bio-molecules like proteins, thermolabile and 
hydrophobic drugs 
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